Publications
5233 Results
- Journal / Conference
- International Journal of Cancer Jan 15;152(2):123-136
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35904874
- PMC
- PMC9691576
- Study Number(s)
- CTSU/C80405
Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)
- Journal / Conference
- Lancet Oncology
- Year
- 2023
- Research Committee(s)
- Breast
- PMC
- https://www.sciencedirect.com/science/article/pii/S1470204522007392?dgcid=author
- Study Number(s)
- S1416
Results of a Phase II Randomized Trial of Cisplatin With ABT-888 (Veliparib) or Placebo in Metastatic Triple-Negative Breast Cancer and/or BRCA1/2 Mutation-Associated Breast Cancer (S1416)
- Journal / Conference
- Journal of the National Cancer Institute Jan 10;djad003. doi: 10.1093/jnci/djad003. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Lung
- PMID
- PMID36625510
- PMC
- https://pubmed.ncbi.nlm.nih.gov/36625510/
- Study Number(s)
- S1400I
Quality-of-life outcomes and risk-prediction for advanced lung cancer treated with Nivolumab/Ipilimumab vs Nivolumab
- Journal / Conference
- Nutrition and Cancer 74(1):141-148
- Year
- 2022
- Research Committee(s)
- Cancer Control
- PMID
- PMID33511883
- PMC
- PMC8319215
- Study Number(s)
- SWOG-9217
Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial
- Journal / Conference
- International Journal of Cancer, Jan 15;150(2):279-289. doi: 10.1002/ijc.33810. Epub 2021 Oct 5
- Year
- 2022
- Research Committee(s)
- Breast and Gastrointestinal
- PMID
- PMID34528705
- Study Number(s)
- CTSU/C40503, CTSU/C80405
Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens
- Journal / Conference
- Clinical Cancer Research, Jan 15;28(2):271-278
- Year
- 2022
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID34716198
- PMC
- PMC8776596
- Study Number(s)
- S1609
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
- Journal / Conference
- Oncogene Jan;41(2):260-267
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID34728807
- PMC
- PMC8738154
- Study Number(s)
- CTSU/C80405
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
- Journal / Conference
- Endocrine-Related Cancer Jan 20;29(2):99-109. doi: 10.1530/ERC-21-0107
- Year
- 2022
- Research Committee(s)
- Cancer Control
- PMID
- PMID34889205
- PMC
- PMC8776589
- Study Number(s)
- SWOG-9217
Serum Markers, Obesity and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
- Journal / Conference
- Journal of the National Cancer Institute Mar 8;114(3):372-380; Jan 4;djab210. doi: 10.1093/jnci/djab210. Online ahead of print.
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID34981117
- PMC
- PMC8902339
- Study Number(s)
- S1417CD
S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
- Journal / Conference
- European Urology Jan 11;S0302-2838(21)02271-5. doi: 10.1016/j.eururo.2021.12.023. Online ahead of print
- Year
- 2022
- Research Committee(s)
- Cancer Control and Prevention and Epidemiology
- PMID
- PMID35031163
- Study Number(s)
- S0000, SWOG-9217